ProShares Ultra NASDAQ Biotechnology
BIB
BIB
29 hedge funds and large institutions have $42.3M invested in ProShares Ultra NASDAQ Biotechnology in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
56% less call options, than puts
Call options by funds: $5.97M | Put options by funds: $13.6M
Holders
29
Holding in Top 10
2
Calls
$5.97M
Puts
$13.6M
Top Buyers
| 1 | +$7.6M | |
| 2 | +$5.05M | |
| 3 | +$863K | |
| 4 |
Morgan Stanley
New York
|
+$844K |
| 5 |
ACP
Aviance Capital Partners
Naples,
Florida
|
+$682K |
Top Sellers
| 1 | -$4.39M | |
| 2 | -$1.59M | |
| 3 | -$740K | |
| 4 |
FTUS
Flow Traders U.S.
New York
|
-$662K |
| 5 |
BCM
Blume Capital Management
Berkeley,
California
|
-$31K |